Tirzepatide Before & After: A Tirzepatide Review From a Real Mochi Patient

Cicily’s Before and After with Tirzepatide

‍Cicily's journey with Mochi Health and Tirzepatide has been a resounding success, culminating in a total weight loss of over 36 pounds and counting. We are so excited for Cicily and look forward to seeing what else she will accomplish!

Mochi Health’s Personalized Approach to Weight Loss Medication

Mochi Health stands out for its commitment to personalized treatment plans, ensuring each patient receives a tailored approach to weight loss. By evaluating individual needs and goals, Mochi Health crafts medication prescriptions that align with personal health objectives. Their process involves thorough consultation, detailed evaluation, and ongoing monitoring, all aimed at ensuring the safe and effective use of weight loss medications. This tailored approach not only caters to the physical aspects of weight loss but also supports the emotional and psychological journey of each patient, much like Cicily's successful experience.

See if you’re eligible to join Mochi Health today and schedule your appointment with a healthcare provider to learn more about the medications offered through Mochi Health. We are here to see you succeed on your weight loss journey!

References:

1. Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A; SURMOUNT-1 Investigators. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022 Jul 21;387(3):205-216. doi: 10.1056/NEJMoa2206038. Epub 2022 Jun 4. PMID: 35658024. https://www.nejm.org/doi/full/10.1056/NEJMoa2206038

2. Willard, F. S., Douros, J. D., Gabe, M. B., Showalter, A. D., Wainscott, D. B., Suter, T. M., Capozzi, M. E., van der Velden, W. J., Stutsman, C., Cardona, G. R., Urva, S., Emmerson, P. J., Holst, J. J., D'Alessio, D. A., Coghlan, M. P., Rosenkilde, M. M., Campbell, J. E., & Sloop, K. W. (2020). Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI insight, 5(17), e140532. https://europepmc.org/article/pmc/pmc7526454

3. Karrar HR, Nouh MI, Nouh YI, Nouh MI, Khan Alhindi AS, Hemeq YH, Aljameeli AM, Aljuaid JA, Alzahrani SJ, Alsatami AA, Alkredees MA, Almuqati AO, Abanmi SN, Alshehri AM. Tirzepatide-Induced Gastrointestinal Manifestations: A Systematic Review and Meta-Analysis. Cureus. 2023 Sep 27;15(9):e46091. https://www.cureus.com/articles/170540#!/

This post was written by our team of health writers for informational purposes only and does not constitute medical advice. Always consult your doctor or healthcare provider for personalized guidance regarding your health. Ozempic®, Wegovy®, Mounjaro®, and Zepbound® and their delivery device are registered trademarks. Mochi Health is a telehealth clinic that offers prescriptions for these products by medical necessity only as determined by a licensed health provider.